Century Therapeutics (IPSC) EBT (2020 - 2026)

Century Therapeutics (IPSC) has reported EBT for 7 consecutive years, with -$90.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 218.75% year-over-year to -$90.9 million; the TTM figure through Mar 2026 stood at -$167.4 million (down 730.63% YoY), while the FY2025 annual figure was $44000.0, up 100.04% from the prior year.
• EBT eased to -$90.9 million in Q1 2026 per IPSC's latest filing, from -$9.5 million in the prior quarter.
• Across five years, EBT topped out at $76.6 million in Q1 2025 and bottomed at -$90.9 million in Q1 2026.
• Historically, EBT has averaged -$28.3 million across 5 years, with a median of -$31.6 million in 2022.
• Annual changes were most pronounced in 2025 — EBT surged 372.83% — and 2026, when it plunged 218.75%.
• Century Therapeutics' EBT stood at -$31.6 million in 2022, then retreated by 27.23% to -$40.3 million in 2023, then climbed by 14.83% to -$34.3 million in 2024, then jumped by 72.16% to -$9.5 million in 2025, then slumped by 852.26% to -$90.9 million in 2026.
• Business Quant data shows IPSC's EBT at -$90.9 million in Q1 2026, -$9.5 million in Q4 2025, and -$34.4 million in Q3 2025.